Fragment-based Approaches for Acylated Peptide Synthesis; An Analysis of Cost and Capacity

Acylated peptide are required in multi-tonne amounts for treating type-2 diabetes and obesity. This contribution will focus on cost and capacity models for fragment-based approaches and compare this with linear SPPS.

About the Speaker

Leendert van den Bos

Chief Executive Officer at EnzyTag BV

Leendert van den Bos obtained his MSc- and PhD-degree in bio-organic chemistry from Leiden University. He joined Organon BioSciences as a Scientist in 2007 and worked subsequently for Schering-Plough, Merck Sharp & Dohme and Aspen Pharmacare mostly in the field of Process Research & Development. End of 2018, he co-founded EnzyTag and serves as CEO since then. Leendert holds an Executive MBA from Nyenrode University. In 2022, he co-founded the biotech start-up GlycoTheraperutics focusing on developing carbohydrate-based molecules that serve as new checkpoint

Webinars